Please use this identifier to cite or link to this item:
Title: Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study.
Austin Authors: Ha, Francis J;Spain, Lavinia;Dowling, Anthony;Kwan, Edmond M;Pezaro, Carmel;Day, Daphne;Chia, Puey Ling ;Tran, Ben;Pook, David;Weickhardt, Andrew J 
Affiliation: Department of Medical Oncology, St Vincent's Hospital, Melbourne, Victoria, Australia
Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Department of Medical Oncology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
Eastern Health and Monash University, Melbourne, Victoria, Australia
Department of Medical Oncology, Monash Health, Melbourne, Victoria, Australia
Issue Date: 30-Jan-2019 2019
Publication information: Asia-Pacific journal of clinical oncology 2019; 15(5): e97-e102
Abstract: Targeted therapy (TT) has improved survival for metastatic renal cell carcinoma (mRCC). However, survival is usually limited if brain metastases (BMs) develop. We aimed to evaluate survival outcomes in mRCC patients based on timing of BM diagnosis. We conducted a multicenter, retrospective study of mRCC patients with BM who received TT at any point between 2005 and 2014. We determined overall survival (OS) from stage IV diagnosis, TT initiation and BM diagnosis, and prognostic factors. Patients were grouped into three categories: synchronous-BM, metachronous-BM diagnosed while conservatively managed (metachronous-BM before TT) and metachronous-BM diagnosed during TT. Survival was calculated by Kaplan-Meier method and predictors were calculated using Cox hazards regression. Incidence of BM was 17% in mRCC patients treated with TT (two centers). Fifty-four mRCC-BM patients were identified from five tertiary centers. Twenty-eight percentage (15/54) had synchronous-BM, 28% (15/54) had metachranous-BM before TT and 44% (24/54) had metachronous-BM during TT. Most had central nervous system (CNS) symptoms at BM diagnosis (78%; 42/54). Median OS from stage IV diagnosis, TT commencement and BM diagnosis was 28 months (95% confidence interval [CI] 16-43), 19 months (95% CI 9-26) and 9 months (95% CI 5-16), respectively. Synchronous-BM group trended toward poorer survival from TT commencement (P = 0.06). Metachronous-BM during TT group had lower survival from BM diagnosis than synchronous-BM and metachronous-BM before TT group (P < 0.001). Eight of 50 deaths (16%) were from neurological complications. The presence of CNS symptoms did not predict worse survival from stage IV diagnosis (P = 0.73). In patients with mRCC, the development of BM while on TT portends shorter prognosis compared with synchronous diagnosis of BM at stage IV disease or metachronous BM developed prior to commencing TT. The presence of CNS symptoms does not predict worse survival.
DOI: 10.1111/ajco.13109
ORCID: 0000-0003-3206-5725
PubMed URL: 30701671
Type: Journal Article
Subjects: brain metastasis
renal cell carcinoma
targeted therapy
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Nov 25, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.